ir.intelliatx.com – MashupMD

Mashup Score: 3

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - Intellia Therapeutics - 5 hour(s) ago

The Investor Relations website contains information about Intellia Therapeutics’s business for stockholders, potential investors, and financial analysts.

Source: ir.intelliatx.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- Amyloidosisfdn
  
  Great news! Read the full press release here: https://t.co/KEdPGdaOqL https://t.co/zBs8hlvF72

Mashup Score: 14

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Intellia Therapeutics - 1 year(s) ago

The Investor Relations website contains information about Intellia Therapeutics’s business for stockholders, potential investors, and financial analysts.

Source: ir.intelliatx.com

Categories: General Medicine News, Cardiologists

Tweet Tweets with this article
- pnatarajanmd
  
  FDA clears ph3 trial of @intelliatx’s in vivo CRISPR-based gene editing of ATTR cardiomyopathy https://t.co/QpuhGajFp5